Kidney Cancer

Patients with advanced renal cell carcinoma whose disease has progressed on first-line therapies may benefit from the combination of Fruzaqla and Tyvyt.

Dr. Ravi Munver discusses how minimally invasive techniques allow patients to preserve kidney function and practical guidance for navigating treatment.

Remote monitoring has been found to be associated with improved postsurgical recovery for patients with cancer.

As September concludes, the landscape of GU oncology continues to evolve, with important developments in prostate, bladder, kidney and other cancers.

This guide on stage 2 kidney cancer covers key info, treatments and what to expect, helping you prepare for informed discussions with your care team.

Molecular testing helps distinguish kidney cancer subtypes, ensuring patients get accurate diagnoses and treatment plans, avoiding unnecessary surgery.

Dr. Ravi Munver sat down for an interview with CURE to discuss progress in kidney cancer care.

I reflect on how my family and friends showed love in different ways during the early days of my chronic cancer diagnosis.

Researchers have created a novel immunotherapy for metastatic kidney cancer that could provide a new treatment option for patients with limited options.

Early-stage kidney cancer is limited to the kidney, usually under seven centimeters and often has a very good prognosis when treated promptly.

Kristen Dahlgren of the Cancer Vaccine Coalition spoke with CURE about why she remains hopeful for the future or cancer vaccines.

It is important to expand clinical trial access for patients with kidney cancer in order to ensure a representative study population.

Dr. Wenxin (Vincent) Xu discussed the benefit of using biomarkers to more precisely guide treatment for patients with renal cell carcinoma.

TAMs may help predict response to PD-1 inhibitors in metastatic clear cell kidney cancer, Dr. Berkay Simsek reported at the 2025 Kidney Cancer Summit.

Six-time survivor Staci Kirk founded the Stiletto Boss Foundation to provide community, support and practical help for women of color beyond treatment.

A dual cancer diagnosis rewired how I live, love, and show up in the world — with presence, purpose, and unapologetic passion.

Fotivda preserved quality-of-life scores in kidney cancer, with better outcomes in second-line use and no added benefit from combining with Opdivo.

PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.

Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated clear cell renal cell carcinoma.

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes.

Q-TWiST may help patients with advanced kidney cancer and their doctors weigh treatment options by focusing on quality of life, not just disease control.

Stereotactic body radiotherapy costs less and has shown better safety compared with immunotherapy and tyrosine kinase inhibitors in patients kidney cancer.

Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell carcinoma, a type of kidney cancer.